厄洛替尼治疗非小细胞肺癌的机制、现状与展望

中国药物警戒 ›› 2010, Vol. 7 ›› Issue (10): 617-619.

厄洛替尼治疗非小细胞肺癌的机制、现状与展望

赵燕¹, 张茹²

1. 国家食品药品监督管理局药品评价中心,北京100045；
2. 中国人民解放军总医院军医进修学院南楼消化科,北京100853

收稿日期:2016-03-12 修回日期:2016-03-12 出版日期:2010-10-08 发布日期:2016-03-09
通讯作者: 张茹,女,博士,老年病诊治。E-mail:5330248@163.com
作者简介:赵燕,女,硕士,药物警戒与药品不良反应监测。

The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer

ZHAO Yan¹, ZHANG Ru²

1.Center for Drug Reevaluation, SFDA, Beijing 100045, China;
2.Department of Gastroenterology, Chinese PLA General Hospital, Beijing 100853

Received:2016-03-12 Revised:2016-03-12 Online:2010-10-08 Published:2016-03-09

摘要/Abstract

摘要： 概述厄洛替尼治疗非小细胞肺癌的作用机制、临床应用现状及常见、严重不良反应,指出其在非小细胞肺癌治疗中的应用前景。

关键词: 厄洛替尼, 非小细胞肺癌, 机制, 展望

Abstract: By overviewing the mechanism ,clinical application and adverse drug reaction(ADR) of erlotinib, to indicate its perspective in the therapy of non-small cell lung cancer.

Key words: erlotinib, non-small cell lung cancer(NSCLC), mechanism, perspective

中图分类号:

R734.2

赵燕, 张茹. 厄洛替尼治疗非小细胞肺癌的机制、现状与展望[J]. 中国药物警戒, 2010, 7(10): 617-619.

ZHAO Yan, ZHANG Ru. The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer [J]. Chinese Journal of Pharmacovigilance, 2010, 7(10): 617-619.

[1] American Cancer Society. Cancer Facts and Figures 2008 [EB/OL]. 2009-07-13[2010-06-25].http://www.cancer.org/downloads/STT/ 2008CAFFfinalsecured.pdf.
[2] World Health Organization. Fact Sheet No. 310[EB/OL]. 2009-0713[2010-06-25]. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
[3] Postmus P E, Smit E F. Chemotherapy for brain metastases of lung cancer: a Review[J]. Ann Oncol, 1999, 10(7): 753-759.
[4] Endelsohn J, Baselga J. Status of the epidermal growth factor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003,21(14): 2787-2799.
[5] Herbst R S, ShinD M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy[J]. Cancer,2002, 94(5): 1593-1611.
[6] Metro G, Finocchiaro G, Cappuzzo F. Anti-cancer therapy with EGFR inhibitors:factors of prognostic and predictive significance[J]. Ann Oncol,2006,17(suppl 2):842-845.
[7] Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomized, open-label , first-line study of gefitinib ( G ) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer(NSCLC) [J]. Ann Oncol,2008,19 (suppl 8): 1-4.
[8] Hirsch F R, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis[J].J Clin Oncol,2003,21:3798-3807.
[9] Hirsch F R, Varella-Garcia M, Bunn P A Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer[J]. J Clin Oncol,2006, 24:5034-5042.
[10] Tsao M S, Sakurada A, Cutz J C, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome[J]. N Engl J Med,2005, 353:133-144.
[11] ShepherdF A, RodriguesP J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer[J].N Engl J Med, 2005, 353(2): 123-132.
[12] Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from “never smokers”and are associated with sensitivity of tumors to gefi tinib and erlotinib [J]. Proc Natl Acad Sci USA, 2004, 101(36):13306-13311.

[1]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[2]	辛灵怡, 杨洋, 朱婧, 何娜, 张静媚, 王航天, 陈琴华, 杨光义. 重楼抗肿瘤活性成分分类及作用机制研究进展[J]. 中国药物警戒, 2024, 21(2): 235-240.
[3]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[4]	杨珍珍, 常成, 高娜, 张晓林, 宋银森, 刘颖, 范天黎. 基于网络药理学和体外研究探讨木犀草素抑制食管鳞状细胞癌的分子机制[J]. 中国药物警戒, 2023, 20(9): 992-1001.
[5]	何佳, 金艳, 赵玉洋, 周骏辉, 李晓琳, 袁媛, 付璐. 有毒中草药炮制减毒方法研究进展[J]. 中国药物警戒, 2023, 20(9): 1064-1070.
[6]	张冰, 萨日娜, 张晓朦, 张丹, 林志健, 王雨. 药源性心脏毒性研究进展[J]. 中国药物警戒, 2023, 20(8): 841-847.
[7]	李亚梅, 水荣. 托法替尼治疗幼年特发性关节炎研究进展[J]. 中国药物警戒, 2023, 20(8): 956-960.
[8]	陈林珍, 王璇, 张晓朦, 马志强, 陆珊, 吴嘉瑞, 赵崇军, 张冰. 基于斑马鱼模型的杠柳毒苷肝毒性评价[J]. 中国药物警戒, 2023, 20(7): 742-748.
[9]	苏月芬, 郑婧柔, 宫贺, 谢广通, 张洁, 赛春梅. 乳腺结重痛轻凝胶贴膏的成型性及治疗乳腺增生作用机制研究[J]. 中国药物警戒, 2023, 20(7): 783-790.
[10]	吕鹏, 张京莉, 王运红, 马芬芬, 张玉, 黄怡菲. 伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展[J]. 中国药物警戒, 2023, 20(5): 595-600.
[11]	李盟, 李容容, 刘成海. 中草药引起肝损伤的临床诊治与用药[J]. 中国药物警戒, 2023, 20(2): 127-131.
[12]	袁琪, 王颖娴, 陈思颖, 尤海生. 1例盐酸厄洛替尼片致严重皮肤溃疡和角膜穿孔的药学监护[J]. 中国药物警戒, 2023, 20(2): 206-208.
[13]	林琦琪, 李馨阳, 孟繁浩. 非小细胞肺癌培美曲塞的耐药机制研究[J]. 中国药物警戒, 2023, 20(11): 1201-1208.
[14]	梁艳, 闫加庆, 杨珺. 注射用培美曲塞二钠致双侧小腿罕见硬皮样皮肤1例分析[J]. 中国药物警戒, 2023, 20(11): 1293-1295.
[15]	蒋建东. 我国儿童药品研发与临床用药安全展望[J]. 中国药物警戒, 2023, 20(1): 1-6.